6–12 hours (short-acting) / 24–48 hours (long-acting)
- — Anxiety
- — yawning
- — muscle aches
- — lacrimation
- — runny nose
- — sweating
- — insomnia
Opioid Use Disorder in Louisville, KY
Opioid Use Disorder (OUD) is a chronic, treatable brain disease defined by compulsive opioid use despite harmful consequences.
Overview
What opioid use disorder looks like.
Opioid Use Disorder (OUD) is a chronic, treatable brain disease defined by compulsive opioid use despite harmful consequences. OUD includes addictions to prescription pain medications (oxycodone, hydrocodone), heroin, and illicit fentanyl. Medication-Assisted Treatment (MAT) paired with behavioral therapy is the clinical standard of care and is a first-line medication for opioid use disorder.
Also known as: opioid addiction, opiate addiction, OUD, narcotic addiction.
Signs of use
What patients and families actually notice.
- Taking opioids in larger amounts or for longer than intended
- Unsuccessful attempts to cut down or stop
- Spending significant time obtaining, using, or recovering from opioids
- Strong cravings or urges to use
- Failing work, family, or school obligations due to opioid use
- Continued use despite social or interpersonal problems
- Using in physically hazardous situations (e.g., driving)
- Tolerance (needing more for the same effect) and withdrawal when stopping
Withdrawal timeline
What withdrawal tends to look like.
Every person's experience varies. The windows below describe typical clinical patterns — your plan will be adjusted based on how you respond.
1–3 days
- — Peak discomfort: nausea
- — vomiting
- — diarrhea
- — abdominal cramps
- — dilated pupils
- — piloerection ("cold turkey")
3–7 days
- — Acute physical symptoms subside
- — residual insomnia
- — dysphoria
- — cravings
Weeks 2–8+
- — Post-acute withdrawal: mood disturbance
- — anhedonia
- — sleep disruption
- — persistent cravings — highest relapse-risk window
Treatment approach
How we will treat opioid use disorder.
Withdrawal management, before admission
Supervised withdrawal with nursing monitoring. Buprenorphine (Suboxone/Subutex) induction is often started during detox to reduce severity and prevent relapse. Withdrawal management is completed before admission to Golden Grove.
Residential treatment
Residential care addresses behavioral and psychological drivers of OUD and stabilizes MAT dosing.
Medication-Assisted Treatment
Golden Grove's MAT for opioid use disorder will be Suboxone, Subutex, and Vivitrol, delivered inside residential care. MAT is the clinical standard of care for opioid use disorder and substantially reduces overdose risk when continued long-term. Methadone is also FDA-approved for OUD, but it's delivered through separate licensed opioid treatment programs, not at Golden Grove.
Integrated dual-diagnosis care
Opioid use disorder often co-occurs with depression, anxiety, and post-traumatic stress disorder (PTSD). Golden Grove will treat these together with the addiction rather than in sequence.
In Kentucky
The local picture.
Kentucky continues to have one of the highest opioid overdose rates in the United States, driven primarily by illicit fentanyl. Louisville (Jefferson County) consistently ranks among the highest-impact counties. Kentucky Medicaid covers medication-assisted treatment for opioid use disorder across all six managed care organizations (MCOs), and Kentucky law supports access to buprenorphine and naloxone.
Kentucky Medicaid coverage
Opioid Use Disorder is typically covered.
Kentucky Medicaid plans typically cover medication-assisted treatment and the clinical continuum of substance use treatment for opioid use disorder, and Golden Grove will also work with most major insurance plans. Golden Grove's MAT for opioid use disorder is Suboxone, Subutex and Vivitrol, delivered inside residential care; methadone is a Kentucky Medicaid benefit provided through separate licensed opioid treatment programs, not at Golden Grove. Coverage check happens on the call.
Coverage is determined by medical necessity using the American Society of Addiction Medicine (ASAM) criteria. Our admissions team verifies your specific plan on the call.
Frequently asked
Common questions.
Is medication-assisted treatment (MAT) just trading one addiction for another?
No. Medication-assisted treatment is the standard of care for opioid use disorder, recommended by SAMHSA and the National Institute on Drug Abuse. MAT medications stabilize brain chemistry without producing a high when taken as prescribed.
How long does MAT last?
MAT is individualized. Some people use it short-term during stabilization, and many benefit from months or years of maintenance. Clinical guidance supports longer-term maintenance. Your clinical team will review the plan with you over time.
Does Kentucky Medicaid cover opioid addiction treatment?
Yes. Kentucky Medicaid plans typically cover opioid use disorder treatment across the clinical continuum of substance use treatment, including MAT.
Why is fentanyl especially dangerous?
Fentanyl is far more potent than heroin or prescription opioids, so the margin between a usual dose and a fatal one is very small, and it's increasingly mixed into other drugs without the person knowing. The risk is highest right after a period of not using, including right after detox, when tolerance has dropped but the old dose feels familiar. That's exactly why medically supervised detox and continued treatment with medication-assisted treatment matter: they lower the relapse-and-overdose risk that comes with lost tolerance.
Is opioid treatment covered by insurance in Louisville?
Golden Grove will accept Kentucky Medicaid through Passport by Molina, will work with most major insurance plans, and self-pay will be an option. Kentucky Medicaid covers medication-assisted treatment for opioid use disorder. Coverage check happens on the call.
Other substances we will treat
The full treatment scope.
Take the next step
Discuss opioid use disorder with our admissions team.
Admissions answers 24/7. Golden Grove will accept Kentucky Medicaid. Coverage check happens on the call.